Literature DB >> 33830235

MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.

Craig Horbinski1,2, Kathleen McCortney2, Roger Stupp2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33830235      PMCID： PMC8099474          DOI： 10.1093/neuonc/noab039

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.

Authors:  Radhika Mathur; Yalan Zhang; Matthew R Grimmer; Chibo Hong; Michael Zhang; Saumya Bollam; Kevin Petrecca; Jennifer Clarke; Mitchel S Berger; Joanna J Phillips; Nancy Ann Oberheim-Bush; Annette M Molinaro; Susan M Chang; Joseph F Costello
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

4.  The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

Authors:  Remco J Molenaar; Dagmar Verbaan; Simona Lamba; Carlo Zanon; Judith W M Jeuken; Sandra H E Boots-Sprenger; Pieter Wesseling; Theo J M Hulsebos; Dirk Troost; Angela A van Tilborg; Sieger Leenstra; W Peter Vandertop; Alberto Bardelli; Cornelis J F van Noorden; Fonnet E Bleeker
Journal:  Neuro Oncol       Date:  2014-02-06       Impact factor: 12.300

5.  MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.

Authors:  Shani Mulholland; Danita M Pearson; Rifat A Hamoudi; Deborah S Malley; Caroline M Smith; Jamie M J Weaver; David T W Jones; Sylvia Kocialkowski; L Magnus Bäcklund; V Peter Collins; Koichi Ichimura
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.316

6.  The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Authors:  Pierre Bady; Sebastian Kurscheid; Mauro Delorenzi; Thierry Gorlia; Martin J van den Bent; Khê Hoang-Xuan; Élodie Vauléon; Anja Gijtenbeek; Roelien Enting; Brian Thiessen; Olivier Chinot; Frédéric Dhermain; Alba A Brandes; Jaap C Reijneveld; Christine Marosi; Martin J B Taphoorn; Wolfgang Wick; Andreas von Deimling; Pim French; Roger Stupp; Brigitta G Baumert; Monika E Hegi
Journal:  Acta Neuropathol       Date:  2018-01-24       Impact factor: 15.887
  6 in total
  1 in total

1.  Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.

Authors:  Beomseok Sohn; Chansik An; Dain Kim; Sung Soo Ahn; Kyunghwa Han; Se Hoon Kim; Seok-Gu Kang; Jong Hee Chang; Seung-Koo Lee
Journal:  J Neurooncol       Date:  2021-10-14       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.